Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.

Adult Humans Isocitrate Dehydrogenase / genetics Consensus Mutation Glioma / diagnosis Brain Neoplasms / diagnosis
D-2HG Isocitrate dehydrogenase (IDH) glioma

Journal

Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420

Informations de publication

Date de publication:
05 01 2023
Historique:
pubmed: 15 10 2022
medline: 11 1 2023
entrez: 14 10 2022
Statut: ppublish

Résumé

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant primary brain tumors diagnosed in patients younger than 50, constituting an important cause of morbidity and mortality. In recent years, there has been significant progress in understanding the molecular pathogenesis and biology of these tumors, sparking multiple efforts to improve their diagnosis and treatment. In this consensus review from the Society for Neuro-Oncology (SNO), the current diagnosis and management of IDH-mutant gliomas will be discussed. In addition, novel therapies, such as targeted molecular therapies and immunotherapies, will be reviewed. Current challenges and future directions for research will be discussed.

Identifiants

DOI: 10.1093/neuonc/noac207 PMID: 36239925 PMC: PMC9825337
pubmed: 36239925
pii: 6761148
doi: 10.1093/neuonc/noac207
pmc: PMC9825337
doi:

Substances chimiques

Isocitrate Dehydrogenase EC 1.1.1.41

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4-25

Subventions

Organisme : NCI NIH HHS
ID : P50 CA097257
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA244838
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Lancet Neurol. 2009 Sep;8(9):810-8
pubmed: 19665931
J Neurooncol. 2017 Sep;134(3):495-504
pubmed: 28382534
Acta Neuropathol. 2021 Jan;141(1):85-100
pubmed: 33216206
Neuro Oncol. 2018 Jan 10;20(1):103-112
pubmed: 29016833
Acta Neuropathol. 2009 Oct;118(4):469-74
pubmed: 19554337
Neuro Oncol. 2021 Nov 2;23(11):1835-1844
pubmed: 34174071
Sci Adv. 2020 Apr 22;6(17):eaaz3221
pubmed: 32494639
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3270-5
pubmed: 21289278
Nat Genet. 2012 Oct;44(10):1122-5
pubmed: 22922872
Eur J Cancer. 2021 May;149:23-33
pubmed: 33819718
Neuro Oncol. 2012 Sep;14 Suppl 4:iv55-64
pubmed: 23095831
Cell Rep. 2018 Oct 23;25(4):1018-1026.e4
pubmed: 30355481
Continuum (Minneap Minn). 2015 Apr;21(2 Neuro-oncology):345-54
pubmed: 25837900
Neuro Oncol. 2020 Nov 26;22(11):1580-1590
pubmed: 32166314
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
Neuro Oncol. 2013 Aug;15(8):979-80
pubmed: 23757293
Clin Cancer Res. 2017 Oct 15;23(20):6078-6085
pubmed: 28751449
J Neurooncol. 2021 Jun;153(2):361-372
pubmed: 34009509
Cell Rep. 2018 Apr 10;23(2):637-651
pubmed: 29642018
Acta Neurochir (Wien). 2013 Dec;155(12):2227-35
pubmed: 24043414
Nature. 2016 Jan 7;529(7584):110-4
pubmed: 26700815
Neurology. 2021 Feb 16;96(7):e1063-e1069
pubmed: 33361259
Cancer Cell. 2022 Sep 12;40(9):939-956.e16
pubmed: 35985343
Nat Genet. 2016 Jan;48(1):59-66
pubmed: 26618343
Continuum (Minneap Minn). 2020 Dec;26(6):1646-1672
pubmed: 33273176
Neuro Oncol. 2022 Apr 1;24(4):624-638
pubmed: 34498069
Cancer Cell. 2010 May 18;17(5):510-22
pubmed: 20399149
Lancet Oncol. 2019 Oct;20(10):e566-e581
pubmed: 31492632
J Clin Invest. 2017 Apr 3;127(4):1425-1437
pubmed: 28319047
J Clin Oncol. 2017 Jul 20;35(21):2439-2449
pubmed: 28640707
Science. 2017 Mar 31;355(6332):
pubmed: 28360267
J Clin Oncol. 2013 Jan 20;31(3):337-43
pubmed: 23071247
Lancet. 2005 Sep 17-23;366(9490):985-90
pubmed: 16168780
Clin Cancer Res. 2019 Sep 15;25(18):5537-5547
pubmed: 31263031
Eur J Surg Oncol. 2020 Dec;46(12):2331-2337
pubmed: 32771251
Sci Transl Med. 2012 Jan 11;4(116):116ra4
pubmed: 22238332
Neuro Oncol. 2001 Jul;3(3):193-200
pubmed: 11465400
Neurosurg Clin N Am. 2021 Apr;32(2):171-180
pubmed: 33781500
Lancet Oncol. 2016 Nov;17(11):1521-1532
pubmed: 27686946
Prog Nucl Magn Reson Spectrosc. 2020 Oct - Dec;120-121:25-71
pubmed: 33198968
J Clin Oncol. 2020 Feb 10;38(5):496-520
pubmed: 31381464
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
Neuro Oncol. 2021 Mar 25;23(3):457-467
pubmed: 32678879
Neuro Oncol. 2022 May 4;24(5):770-778
pubmed: 34751786
World Neurosurg. 2019 Dec;132:e133-e139
pubmed: 31505287
Nature. 2019 Dec;576(7785):112-120
pubmed: 31748746
Ann Neurol. 2015 Sep;78(3):355-74
pubmed: 26017892
Lancet Oncol. 2018 Sep;19(9):1170-1179
pubmed: 30115593
J Clin Oncol. 2002 May 1;20(9):2267-76
pubmed: 11980997
Neuro Oncol. 2021 May 5;23(5):803-811
pubmed: 33130890
Leukemia. 2022 May;36(5):1313-1323
pubmed: 35273342
EMBO Rep. 2011 May;12(5):463-9
pubmed: 21460794
Cancer Res. 2017 Apr 1;77(7):1709-1718
pubmed: 28202508
Oncotarget. 2015 Apr 20;6(11):8606-20
pubmed: 25825982
Neuro Oncol. 2017 May 1;19(5):719-725
pubmed: 28453748
Nature. 2012 Feb 15;483(7390):484-8
pubmed: 22343896
Neuro Oncol. 2017 Feb 1;19(2):242-251
pubmed: 27571885
Nature. 2021 Apr;592(7854):463-468
pubmed: 33762734
Nat Rev Clin Oncol. 2021 Oct;18(10):645-661
pubmed: 34131315
Acta Neuropathol. 2016 Dec;132(6):917-930
pubmed: 27664011
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Cancer Res. 2017 Aug 1;77(15):4102-4115
pubmed: 28625978
Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):30-34
pubmed: 34919877
Nature. 2016 Nov 10;539(7628):309-313
pubmed: 27806376
J Neurosurg. 2022 Mar 4;:1-8
pubmed: 35245899
J Clin Oncol. 2008 Mar 10;26(8):1338-45
pubmed: 18323558
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Nature. 2009 Dec 10;462(7274):739-44
pubmed: 19935646
BMJ. 2009 Aug 17;339:b3016
pubmed: 19687093
Lancet Oncol. 2011 Jun;12(6):583-93
pubmed: 21474379
Am J Pathol. 2009 Apr;174(4):1149-53
pubmed: 19246647
Lancet. 2002 Nov 2;360(9343):1361-8
pubmed: 12423981
Cancer Cell. 2015 Dec 14;28(6):773-784
pubmed: 26678339
Science. 2013 May 3;340(6132):626-30
pubmed: 23558169
J Pathol. 2012 Jan;226(1):7-16
pubmed: 22072542
Neurooncol Pract. 2020 Aug 29;8(1):40-47
pubmed: 33664968
J Neurooncol. 2019 Nov;145(2):309-319
pubmed: 31549281
Mol Cancer Ther. 2020 Feb;19(2):375-383
pubmed: 31727689
J Clin Oncol. 2020 Oct 10;38(29):3407-3417
pubmed: 32706640
Lancet Oncol. 2017 Jun;18(6):e315-e329
pubmed: 28483413
J Clin Oncol. 2014 Mar 10;32(8):783-90
pubmed: 24516018
J Clin Oncol. 2016 Nov 20;34(33):4030-4039
pubmed: 28248126
Acta Neuropathol. 2018 Jul;136(1):153-166
pubmed: 29687258
Acta Neuropathol. 2020 Oct;140(4):569-581
pubmed: 32776277
Neuro Oncol. 2018 Aug 2;20(9):1262-1271
pubmed: 29438510
Neuro Oncol. 2019 Jul 11;21(7):837-853
pubmed: 30753579
Cancer Cell. 2015 Sep 14;28(3):307-317
pubmed: 26373278
Clin Cancer Res. 2021 Aug 15;27(16):4491-4499
pubmed: 34078652
Cancer Res. 2013 Jan 15;73(2):496-501
pubmed: 23204232
Eur Radiol. 2021 Jul;31(7):5289-5299
pubmed: 33409784
Neurology. 2010 Jun 8;74(23):1886-90
pubmed: 20427748
Science. 2011 Sep 9;333(6048):1453-5
pubmed: 21817013
Cancer Res. 2017 Nov 15;77(22):6097-6108
pubmed: 28939681
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
Neurosurgery. 2012 Apr;70(4):921-8; discussion 928
pubmed: 21997540
J Pathol. 2020 Apr;250(5):532-540
pubmed: 32073140
Cell. 2018 Sep 20;175(1):101-116.e25
pubmed: 30220459
Acta Neuropathol Commun. 2016 Mar 31;4:31
pubmed: 27036230
J Neurooncol. 2019 Oct;145(1):115-123
pubmed: 31556015
Nat Genet. 2011 Nov 06;43(12):1256-61
pubmed: 22057234
Nat Genet. 2021 Jul;53(7):1088-1096
pubmed: 34045764
Neuro Oncol. 2014 Jan;16(1):81-91
pubmed: 24305719
Nature. 2012 Feb 15;483(7390):479-83
pubmed: 22343889
Ann Oncol. 2021 Feb;32(2):171-182
pubmed: 33246022
Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10743-10748
pubmed: 28916733
Cancer Cell. 2011 Jan 18;19(1):17-30
pubmed: 21251613
Nature. 2020 Apr;580(7804):517-523
pubmed: 32322066
Cancer. 1975 Jun;35(6):1551-7
pubmed: 1148989
Science. 2011 Jul 22;333(6041):425
pubmed: 21719641
Neuro Oncol. 2021 May 5;23(5):858-860
pubmed: 33830235
Neuro Oncol. 2022 Aug 1;24(8):1219-1229
pubmed: 35380705
J Clin Oncol. 2011 Dec 1;29(34):4482-90
pubmed: 22025148
Sci Transl Med. 2017 Feb 1;9(375):
pubmed: 28148839
Neuro Oncol. 2021 Nov 2;23(11):1872-1884
pubmed: 33823014
Neuro Oncol. 2020 Jun 9;22(6):830-837
pubmed: 32002556
Nat Med. 2018 Aug;24(8):1192-1203
pubmed: 29988124
Lancet Oncol. 2021 Jun;22(6):813-823
pubmed: 34000245
Neuro Oncol. 2016 Feb;18(2):283-90
pubmed: 26691210
JCO Precis Oncol. 2021 Nov;5:466-472
pubmed: 34994649
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Cancer Res. 2014 Jun 15;74(12):3317-31
pubmed: 24755473
Neuro Oncol. 2004 Oct;6(4):300-5
pubmed: 15494097
Clin Cancer Res. 2014 Jun 1;20(11):2898-909
pubmed: 24714777
Brain Pathol. 2015 Nov;25(6):769-80
pubmed: 26526945
Cancer Res. 2010 Nov 15;70(22):8981-7
pubmed: 21045145
Cancer Cell. 2003 Aug;4(2):133-46
pubmed: 12957288
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
Mol Cancer Res. 2016 Oct;14(10):976-983
pubmed: 27430238
J Clin Oncol. 2020 Oct 10;38(29):3398-3406
pubmed: 32530764
Epilepsia. 2012 Jan;53(1):51-7
pubmed: 21933181
Cancer. 2020 Apr 1;126(7):1379-1389
pubmed: 31967671
Neurology. 2017 May 9;88(19):1805-1813
pubmed: 28404805
Neuro Oncol. 2020 Dec 18;22(12):1822-1830
pubmed: 32328652
Neuro Oncol. 2014 Mar;16(3):414-20
pubmed: 24305712
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Cancer. 2000 Jun 1;88(11):2606-18
pubmed: 10861440
Oncotarget. 2012 Jul;3(7):709-22
pubmed: 22869205
Neuro Oncol. 2018 Jun 18;20(7):907-916
pubmed: 29126125
Neuro Oncol. 2021 May 5;23(5):812-826
pubmed: 33049063
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56
pubmed: 8948338
JAMA. 2012 Nov 14;308(18):1881-8
pubmed: 23099483
J Natl Compr Canc Netw. 2020 Nov 02;18(11):1537-1570
pubmed: 33152694
Neurology. 2021 May 4;:
pubmed: 33947781
Clin Cancer Res. 2018 Apr 1;24(7):1705-1715
pubmed: 29339439
Neurology. 1991 Nov;41(11):1741-4
pubmed: 1658684
J Neurosurg. 2020 Jun 05;134(6):1728-1737
pubmed: 32502996
Radiother Oncol. 2019 Aug;137:95-101
pubmed: 31082632
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
Acta Neuropathol. 2022 Feb;143(2):263-281
pubmed: 34967922
Nat Genet. 2018 Jan;50(1):62-72
pubmed: 29180699
Clin Cancer Res. 2016 Apr 1;22(7):1632-41
pubmed: 26534967
Cancer Res. 2006 Oct 15;66(20):9852-61
pubmed: 17047046
Nature. 2012 Feb 15;483(7390):474-8
pubmed: 22343901
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6
pubmed: 23530248
Neurooncol Adv. 2022 Mar 01;4(1):vdac030
pubmed: 35386566
Cancer Discov. 2020 Nov;10(11):1672-1689
pubmed: 32606138
Science. 2015 May 29;348(6238):1036-9
pubmed: 25977370
Neurology. 2013 Oct 22;81(17):1515-22
pubmed: 24068788
J Neurooncol. 2020 May;147(3):515-524
pubmed: 32270374
Science. 2014 Jan 10;343(6167):189-193
pubmed: 24336570
J Clin Oncol. 2013 Jan 20;31(3):344-50
pubmed: 23071237
Neuro Oncol. 2019 Nov 4;21(11):1357-1375
pubmed: 31301133
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945

Auteurs

Julie J Miller (JJ)

Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

L Nicolas Gonzalez Castro (LN)

Harvard Medical School, Boston, MA, USA.
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
ORCID: 0000-0001-7699-5188

Samuel McBrayer (S)

Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, Texas, 75235, USA.

Michael Weller (M)

Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.
ORCID: 0000-0002-1748-174X

Timothy Cloughesy (T)

UCLA Neuro-Oncology Program, Los Angeles, CA, USA.

Jana Portnow (J)

Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Ovidiu Andronesi (O)

Harvard Medical School, Boston, MA, USA.
Department of Radiology, Massachusetts General Hospital, Boston, MA, USA.

Jill S Barnholtz-Sloan (JS)

Informatics and Data Science (IDS), Center for Biomedical Informatics and Information Technology (CBIIT), Trans-Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute (NCI), Bethesda, MD, USA.

Brigitta G Baumert (BG)

Cantonal Hospital Graubunden, Institute of Radiation-Oncology, Chur, Switzerland.

Mitchell S Berger (MS)

Department of Neurosurgery, University of California-San Francisco, San Francisco, California, USA.
ORCID: 0000-0003-1983-4892

Wenya Linda Bi (WL)

Harvard Medical School, Boston, MA, USA.
Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA.

Ranjit Bindra (R)

Department of Therapeutic Radiology, Brain Tumor Center, Yale School of Medicine, New Haven, CT, USA.
ORCID: 0000-0002-3255-0467

Daniel P Cahill (DP)

Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID: 0000-0003-2552-6546

Susan M Chang (SM)

Department of Neurosurgery, University of California-San Francisco, San Francisco, California, USA.

Joseph F Costello (JF)

Department of Neurosurgery, University of California-San Francisco, San Francisco, California, USA.

Craig Horbinski (C)

Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Northwestern Medicine Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
ORCID: 0000-0001-8340-9992

Raymond Y Huang (RY)

Harvard Medical School, Boston, MA, USA.
Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Robert B Jenkins (RB)

Individualized Medicine Research, Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, Minnesota 55901, USA.
ORCID: 0000-0002-4049-694X

Keith L Ligon (KL)

Harvard Medical School, Boston, MA, USA.
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Ingo K Mellinghoff (IK)

Department of Neurology, Evnin Family Chair in Neuro-Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

L Burt Nabors (LB)

Department of Neurology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama, USA.

Michael Platten (M)

CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.

David A Reardon (DA)

Harvard Medical School, Boston, MA, USA.
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.

Diana D Shi (DD)

Harvard Medical School, Boston, MA, USA.
Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

David Schiff (D)

Division of Neuro-Oncology, Department of Neurology, University of Virginia Health System, Charlottesville, Virginia, USA.

Wolfgang Wick (W)

Neuro-Oncology at the German Cancer Research Center (DKFZ), Program Chair of Neuro-Oncology at the National Center for Tumor Diseases (NCT), and Neurology and Chairman at the Neurology Clinic in Heidelberg, Heidelberg, Germany.
ORCID: 0000-0002-6171-634X

Hai Yan (H)

Genetron Health Inc, Gaithersburg, Maryland 20879, USA.

Andreas von Deimling (A)

Department of Neuropathology, University Hospital Heidelberg, and, Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), and, DKTK, INF 224, 69120 Heidelberg, Germany.

Martin van den Bent (M)

Brain Tumour Centre, Erasmus MC Cancer Institute, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands.

William G Kaelin (WG)

Harvard Medical School, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Patrick Y Wen (PY)

Harvard Medical School, Boston, MA, USA.
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Isocitrate dehydrogenase (IDH) mutant gliomas:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Isocitrate dehydrogenase (IDH) mutant gliomas:...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Alcohol oxidoreductases › NAD (+) and NADP (+) dependent Alcohol oxidoreductases › Isocitrate dehydrogenases › Isocitrate dehydrogenase (IDH) mutant gliomas:...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Consensus › Isocitrate dehydrogenase (IDH) mutant gliomas:...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Isocitrate dehydrogenase (IDH) mutant gliomas:...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Isocitrate dehydrogenase (IDH) mutant gliomas:...
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Isocitrate dehydrogenase (IDH) mutant gliomas:...